ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 778-786

  Cozza, Giorgio ^a   Bortolato, Andrea ^a   Menta, Ernesto ^b   Cavalletti, Ennio ^b   Spinelli, Silvano ^b   Moro, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ethical Oncology Science (EOS) SpA   (Italy)

Author keywords

Anticancer drugs; ATP non competitive; Drug discovery; Ser Thr kinase inhibitors

Indexed keywords

1 [1 [4 (7 PHENYL 1H IMIDAZO[4,5 G]QUINOXALIN 6 YL)BENZYL]PIPERIDIN 4 YL] 1,3 DIHYDRO BENZOIMIDAZOL 2 ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [2 (2,8 DIAZA SPIRO[5.5]UNDECANE 2 CARBONYL)HEXYL] 3 M TOLYL 2,3 DIHYDRO 1H QUINAZOLIN 4 ONE; 2 [2 METHOXY 5 [2 (2,4,6 TRIMETHOXY PHENYL)ETHENESULFONYLMETHYL]PHENYLAMINO]PROPIONIC ACID; 2 METHOXY 5 [[2 (2,4,6 TRIMETHOXY PHENYL)ETHENESULFONYLMETHYL]PHENYLAMINO]ACETIC ACID; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 4 (2,3 DIHYDRO BENZO[1,4]DIOXIN 6 YL) 5 (5 NITRO 4H 1LAMBDA 4 THIAZOL 2 YLSULFANYL) 5H [1,2,4]TRIAZOL 3 OL; 4 (4 METHOXY PHENYL) 2 METHYL [1,2,4]THIAZOLIDINE 3,5 DIONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 5 (5 NITRO 4H 1LAMBDA 4 THIAZOL 2 YLSULFANYL) 5H 1LAMBDA 4 [1,3,4]THIADIAZOL 4 YLAMINE; 5 [4 (2,5 DICHLORO PHENOXY)PHENYLAMINO] 3 HYDROXY N (2 HYDROXY 1 METHYL ETHYL) ISOTHIAZOLE 4 CARBOXAMIDINE; 5 BROMO N (2,3 DIHYDROXY PROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODO PHENYLAMINO)BENZAMIDE; [5 [3,4 DIFLUORO 2 (2 FLUORO 4 IODO PHENYLAMINO)PHENYL] [1,3,4]OXADIAZOL 2 YL] (2 MORPHOLIN 4 YL ETHYL)AMINE; ADENOSINE TRIPHOSPHATE; DORAMAPIMOD; FLUORO 1 METHYL 6 OXO 1,6 DIHYDRO PYRIDINE 3 CARBOXYLIC ACID CYCLOPROPYLMETHOXY AMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; ONO 01910; ONO 12380; PD 318088; PD 334581; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; THIAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CRYSTAL STRUCTURE; DRUG COMPETITION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; INFLAMMATORY DISEASE; INHIBITION KINETICS; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR MODEL; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 73449102493     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789056930     Document Type: Review

References (41)

1. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411(6835), 355-365.
2. Hanks, S. K.; Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J., 1995, 9(8), 576-596.
3. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S.J. The protein kinase complement of the human genome. Science, 2002, 298(5600), 1912-34.
4. Sawyers, C.L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev., 2003, 17(24), 2998-3010.
5. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. In Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases. Gutkind, J.S., Ed. Totowa: NJ, 2000, pp. 453-465.
6. Kuma, Y.; Sabio, G.; Bain, J.; Shpiro, N.; Márquez, R.; Cuenda, A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem., 2005, 280(20), 19472-19479
7. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Grob, P.M.; Hickey, E.R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol., 2002 , 9(4), 268-272.
8. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 2006, 5(10), 835-844.
9. Wan, P.T.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004 , 116(6), 855-867.
10. Burke, J.R.; Pattoli, M.A.; Gregor, K.R.; Brassil, P.J.; MacMaster, J.F.; McIntyre, K.W.; Yang, X.; Iotzova, V.S.; Clarke, W.; Strnad, J.; Qiu, Y.; Zusi, F.C. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem., 2003, 278(3), 1450-1456.
11. Martinez, A.; Alonso, M.; Castro, A.; Pérez, C.; Moreno, F.J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 2002, 45(6), 1292-1299.
12. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I.; Gelpí, J.L.; Luque, F.J.; Pérez, C.; Moreno, F.J. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J. Med. Chem., 2005, 48(23), 7103-7112.
13. Messersmith, W.A.; Hidalgo, M.; Carducci, M., Eckhardt, S.G. Novel targets in solid tumors: MEK inhibitors. Clin. Adv. Hematol. Oncol., 2006, 4(11), 831-836.
14. Alessi, D.R.; Cuenda, A.; Cohen, P.; Dudley, D.T.; Saltiel, A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem., 1995, 270(46), 27489-27494.
15. Duncia, J.V.; Santella, J.B. 3rd; Higley, C.A.; Pitts, W.J.; Wityak, J.; Frietze, W.E.; Rankin, F.W.; Sun J.H.; Earl R.A.; Tabaka, A.C.; Teleha, C.A.; Blom, K.F.; Favata, M.F.; Manos, E.J.; Daulerio, A.J.; Stradley, D.A.; Horiuchi, K.; Copeland, R.A.; Scherle, P.A.; Trzaskos, J.M.; Magolda, R.L.; Trainor, G.L.; Wexler, R.R.; Hobbs, F.W.; Olson, R.E. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett., 1998, 8(20), 2839-28344.
16. Delaney, A.M.; Printen, J.A.; Chen, H.; Fauman, E.B.; Dudley, D.T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol., 2002, 22(21), 7593-602.
17. Barrett, S.D.; Bridges, A.J.; Dudley, D.T.; Saltiel, A.R.; Fergus, J.H.; Flamme, C.M.; Delaney, A.M.; Kaufman, M.; LePage, S.; Leopold, W.R.; Przybranowski, S.A.; Sebolt-Leopold, J.; Van Becelaere, K.; Doherty, A.M.; Kennedy, R.M.; Marston, D.; Howard, W.A. Jr; Smith, Y.; Warmus, J.S.; Tecle, H. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett., 2008, 18(24), 6501-6504.
18. Fischmann, T.; Smith, C.; Mayhood, T.; Myers, J.; Reichert, P.; Mannarino, A.; Carr, D.; Zhu, H.; Wong, J.; Yang, R.S.; Le, H.; Madison, V. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry, 2009, 48(12), 2661-2674.
19. Lorusso, P.M.; Adjei, A.A.; Varterasian, M.; Gadgeel, S.; Reid, J.; Mitchell, D.Y.; Hanson, L.; DeLuca, P.; Bruzek, L.; Piens, J.; Asbury, P.; Van Becelaere, K.; Herrera, R.; Sebolt-Leopold, J.; Meyer, M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol., 2005, 23(23), 5281-5293.
20. Rinehart, J.; Adjei, A.A.; Lorusso, P.M.; Waterhouse, D.; Hecht, J.R.; Natale, R.B.; Hamid, O.; Varterasian, M.; Asbury, P.; Kaldjian, E.P.; Gulyas, S.; Mitchell, D.Y.; Herrera, R.; Sebolt-Leopold, J.S.; Meyer, M.B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol., 2004, 22(22), 4456-4462.
21. Ohren, J.F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W.T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D.T.; Leung, I.K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C.A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol., 2004, 11(12), 1192-1197.
22. Rewcastle, G.W.; Spicer, J.A.; Barrett, S.D.; Kaufman, M.D.; Milbank, J.B.; Tecle, H. N-(4 substituted phenyl)-anthranilic acid hydroxamate ester. US 2006, 7.078.438 B2, 2006.
23. Lorusso, P.M.; Krishnamurthy, S.; Rinehart, J. Phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J. Clin. Oncol., 2005, 23(168), 3011.
24. Yeh, T.C.; Marsh, V.; Bernat, B.A.; Ballard, J.; Colwell, H.; Evans, R.J.; Parry, J.; Smith, D.; Brandhuber, B.J.; Gross, S.; Marlow, A.; Hurley, B.; Lyssikatos, J.; Lee, P.A.; Winkler, J.D.; Koch, K.; Wallace, E. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res., 2007, 13(5), 1576-1583.
25. Chow, L.; Eckhardt, S.G.; Reid, J. Proc. AACR-EORTC-NCI Targeted Ther. Conference., 2005, p. C162.
26. Wallace, E.M.; Lyssikatos, J.; Blake, J.F.; Seo, J.; Yang, H.W.; Yeh, T.C.; Perrier, M.; Jarski, H.; Marsh, V.; Poch, G.; Livingston, M.G.; Otten, J.; Hingorani, G.; Woessner, R.; Lee, P.; Winkler, J.; Koch, K. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. J. Med. Chem., 2006, 49(2), 441-444.
27. El Abdellaoui, H.; Varaprasad, C.V.; Barawkar, D.; Chakravarty, S.; Maderna, A.; Tam, R.; Chen, H.; Allan, M.; Wu, J.Z.; Appleby, T.; Yan, S.; Zhang, W.; Lang, S.; Yao, N.; Hamatake, R.; Hong, Z. Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(21), 5561-5566.
28. Gumireddy, K.; Reddy, M.V.; Cosenza, S.C.; Boominathan, R.; Baker, S.J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E.P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell., 2005, 7(3), 275-286.
29. Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov., 2003, 2(7), 554-565.
30. Bogoyevitch, M. A. Therapeutic promise of JNK ATP-noncompetitive inhibitors. Trends Mol. Med., 2005, 11(5), 232-239.
31. Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; De'rijard, B.; Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J., 1996, 15(11), 2760-2770.
32. Kyriakis, J. M.; Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev., 2001, 81(2), 807-869.
33. Pearson, G.; Robinson, F.; Gibson, T. B.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev., 2001, 22(2), 153-183.
34. De, S.K.; Stebbins, J.L.; Chen, L.H.; Riel-Mehan, M.; Machleidt, T.; Dahl, R.; Yuan, H.; Emdadi, A.; Barile, E.; Chen, V.; Murphy, R.; Pellecchia M. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J. Med. Chem., 2009, 52(7), 1943-52.
35. Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E., Lindsley, C.W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(4), 905-909.
36. Hartnett, J.C.; Barnett, S.F.; Bilodeau, M.T.; Defeo-Jones, D.; Hartman, G.D.; Huber, H.E.; Jones, R.E.; Kral, A.M.; Robinson, R.G.; Wu, Z. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(6), 2194-2197.
37. Calleja, V.; Laguerre, M.; Parker, P.J.; Larijani, B. Role of a novel PH-Kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol., 2009, 7(1), 189-200.
38. Zhou, B. B.; Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer, 2004, 4(3), 216-225.
39. Kong, N.; Fotouhi, N.; Wovkulioch, P. M.; Roberts, Cell cycle inhibitors for the treatment of cancer. J. Drugs Future, 2003, 28(9), 881-886.
40. Kawabe, T. G2 Checkpoint abrogators as anticancer drugs. Mol. Cancer Ther., 2004, 3(4), 513-519.
41. Converso, A.; Hartingh, T.; Garbaccio, R.M.; Tasber, E.; Rickert, K.; Fraley, M.E.; Yan, Y.; Kreatsoulas, C.; Stirdivant, S.; Drakas, B.; Walsh, E.S.; Hamilton, K.; Buser, C.A.; Mao, X.; Abrams, M.T.; Beck, S.C.; Tao W.; Lobell, R.; Sepp-Lorenzino, L.; Zugay-Murphy, J.; Sardana, V.; Munshi, S.K.; Jezequel-Sur, S.M.; Zuck, P.D.; Hartman, G.D. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(4), 1240-1244.